Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Fundación GECP: Clinical Trials & FDA Approval Profile

Fundación GECP (Global / Institutional) sponsors 16 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 12 active protocols (5 recruiting now), 3 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)6.3%
Median Closed Enrollment vs National (145 pts)44 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Fundación GECP
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)16
Active Pipeline (Recruiting Now)12 (5)
Completed vs Stopped Early3 / 1 (6.3%)
Median Closed Actual Enrollment44 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Fundación GECP
Hospital Research SiteLocationShared Protocols
Hospital Universitario Fundación Jiménez DíazMadrid16
Hospital Universitari Vall d'HebronBarcelona13
Hospital de La Santa Creu I Sant PauBarcelona11

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Fundación GECP
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07242547Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC PatientsPhase IIRECRUITING
NCT07153445Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)Phase IIRECRUITING
NCT06431633Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who WerePhase IIIRECRUITING
NCT06917573PALACE: Cemiplimab Trial According to ctDNA LevelsPhase IIRECRUITING
NCT05398094Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapyPhase IIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Fundación GECP Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI